Table of Contents
This medical device patent landscape case study follows a representative scenario: a venture-backed surgical-robotics company preparing a Series B, deciding whether its next-generation instrument arm was clear to build and worth defending. Before committing R&D budget or standing in front of investors, the team needed to know who already owned the crowded space around soft-tissue manipulation. We mapped the field, named the assignees that mattered, and handed back a board-ready readout in six weeks.
The Challenge
The company had a working prototype and a term sheet in sight, but no clear picture of the patent terrain it was entering. Medical technology is one of the most heavily filed fields in the world. In 2024 innovators published 165,823 medical-technology patent applications — 4.9% of all published filings globally, growing 7.1% year on year (WIPO).
At the European Patent Office the picture is just as dense. More than 15,900 medical-technology applications were filed with the EPO in 2025, making it the fourth-largest field at 7.9% of all applications, with an unusually high 77% grant rate. In a field where three quarters of filings mature into enforceable rights, a blind spot is expensive.
The specific worry was surgical robotics. That segment is forecast to grow from roughly $13.7bn in 2025 to about $27.1bn by 2030 (a ~14.7% CAGR, MarketsandMarkets), and the incumbents have been filing against it for a decade. The founders needed to separate genuine freedom to build from the marketing claim that ‘nobody else is doing this.’
Three questions had to be answered before the raise closed. Could the instrument arm be built without walking into a granted claim? If not, which claims had to be designed around, and how hard would that be? And was there any defensible white space the company could claim as its own, so the pitch was about owning something rather than merely avoiding trouble?
The stakes were concrete. A single infringement letter from one of the large incumbents can stall a fundraise, and a redesign forced late in development can cost a hardware startup a year. The readout had to be accurate enough to bet the roadmap on, and plain enough for a non-technical board to act on in a single meeting.
Our Approach
A medical device patent landscape case study is only as good as the search that feeds it, so we started with the classification system rather than keywords. We anchored the search on the Cooperative Patent Classification subclasses that govern the technology: A61B (surgical and diagnostic instruments), A61N (electrotherapy and neurostimulation) and G16H (health informatics), then layered controlled assignee and citation searches on top.
We pulled published applications and granted families across the USPTO, EPO and WIPO PCT collections for the last ten years, de-duplicated them to the family level so one invention was not counted five times, and scored each family for relevance to the instrument-arm claim scope the client actually cared about.
Four steps, in sequence
First, a classification-anchored pull to define the universe. Second, assignee benchmarking to see who the real competitors were by volume and recency. Third, a citation and claim read of the top families to find what was actually enforceable versus merely filed. Fourth, a white-space pass to locate the subclasses where filing density was thin and the client could file first.
Throughout, we treated a filed application differently from a granted claim. The headline filing counts tell you where attention is going; the granted claims tell you where the fences actually are.
Classification anchoring matters in device work because competitors describe the same mechanism in very different language. A keyword search for ‘robotic instrument arm’ misses the family that calls the identical structure a ‘manipulator assembly.’ Both, however, are filed into the same CPC subclass, so starting from A61B 34 caught families a keyword pass would have silently dropped.
We also widened the search across offices on purpose. Roughly 39.7% of EPO medtech filings in 2025 originated in the United States and another 39.7% inside EPO member states, so a US-only search would have under-counted European incumbents who had not yet nationalised in the States. Pulling USPTO, EPO and the WIPO PCT collections together, then collapsing to families, kept the picture honest without inflating it.
Reading claims, not just counting them
For the short-list we read independent claims against the client’s prototype element by element. A granted claim only blocks you if every one of its elements is present in your product; miss one and you are outside it. That element-by-element read is slow, but it is the step that turns a scary pile of hits into a list of real obstacles.
We flagged each in-force family as blocking, design-around, or adjacent, and recorded the single claim element that created the exposure. A board can act on ‘four families block us, each on one element we can engineer around’ far more easily than on a raw count of four hundred.
What the Medical Device Patent Landscape Case Study Found
Three assignee clusters dominated the entry lane. Consistent with public landscape data, the heaviest filers in the broader device space were Terumo, Koninklijke Philips and Medtronic, while surgical-robotics patent volume was led by Johnson & Johnson (~3,283 families), Medtronic (~2,183) and the fast-rising CMR Surgical (~1,048). Two of those three sat squarely across the client’s intended claim scope.
The enforceable core was narrower than the raw counts suggested. Of several hundred families that matched on classification, only a few dozen carried granted, in-force claims that genuinely read on the instrument-arm concept. That distinction mattered: it turned a frightening 400-family search hit into a tractable short-list of real obstacles.
Where the fences were — and were not
The densest granted coverage clustered in A61B 34 (robotic surgery control) and A61B 17 (surgical instruments). Neurostimulation-heavy A61N 1, where Medtronic holds thousands of records, was adjacent but did not block the mechanical claim the client wanted.
Two subclasses were conspicuously thin: a specific sterilisable force-feedback coupling, and a single-port kinematic arrangement. Neither had a granted blocking claim from the three major assignees — the white space the readout was built to surface.
Filed is not the same as enforceable
The split between filing and grant explained the gap. Globally, medical technology slipped about 3% among the top PCT fields in 2025 even as it stayed the fifth-largest, which told us the incumbents were consolidating around earlier filings rather than opening new fronts. Many of the scary hits were abandoned applications and lapsed families carrying no enforceable right at all.
That is the trap a raw count sets. Public landscape data showed every top surgical-robotics filer posting steep year-on-year declines in new filings — a field maturing, not exploding. For the client, a maturing field with identifiable white space was a better place to enter than a land-grab where everything was still in flux.
The Outcome
The client walked into its Series B with a clear-to-file lane rather than a hope. We identified two white-space subclasses the team could file into first, flagged the four granted families worth designing around, and recommended a defensive filing in the force-feedback coupling before a competitor’s pending application matured.
Just as valuable was what we removed from the worry list. The thousands of neurostimulation patents that had spooked the founders were adjacent, not blocking, and the readout said so in plain terms the board could act on. The engineering roadmap shifted toward the two defensible subclasses within the month.
The investors noticed the difference. Instead of a slide claiming no competition — a claim sophisticated life-sciences investors distrust on sight — the company showed a map of who owned what, exactly where its lane sat, and a dated plan to fence that lane with its own filing. A defensible position, honestly argued, is worth more in diligence than an optimistic one.
What This Means for Similar Matters
The lesson from this medical device patent landscape case study generalises to any crowded, high-grant field: filing counts are a map of attention, not a map of risk. In medical technology, where the EPO grants 77% of applications, the gap between ‘filed’ and ‘enforceable’ is where strategy lives.
Classification-first searching beats keyword-first searching in device work, because competitors describe the same mechanism in different words but almost always file into the same CPC subclass. And family-level de-duplication is what turns an unreadable hit list into a decision the board can take in one meeting.
Finally, timing is part of the deliverable. A pending competitor application that has not yet granted is both a risk and an opportunity: file your own improvement before it matures and you may own the fence instead of standing behind it. The readout dated every pending family that mattered so the client could act while the window was open.
Why the Landscape Is So Dense in 2026
Medical technology sits near the top of every major patent register. It was the fifth-largest field in WIPO PCT filings in 2025 at 6.3% of the ~275,900 international applications filed that year, behind digital communication (11.1%), computer technology (9.6%), electrical machinery (9%) and pharmaceuticals (4.3%).
That density is why a structured landscape beats an ad-hoc search. With European patent demand passing 200,000 applications for the first time in 2025 and a global device market near $681bn heading toward $955bn by 2030, the cost of entering blind keeps rising. A disciplined read of the field is cheaper than one avoidable infringement letter.
How to Use a Landscape Like This
Treat the readout as a living document, not a one-off report. The filing data behind it refreshes constantly — the WIPO and EPO figures cited here are annual snapshots of a register that moves every week — so a landscape is most valuable when it is revisited at each major product or fundraising milestone.
Three uses repay the effort. In product planning, it tells engineering which subclasses to design around and which to file into. In fundraising, it replaces an unprovable ‘no competition’ claim with a defensible ownership story. And in budgeting, it ranks where prosecution spend will buy the most protection, so a limited filing budget goes to the two subclasses that actually matter rather than being sprayed across the field.
Who should commission one
Any company about to commit real money to a crowded technology — a hardware startup before a raise, an acquirer before a deal, an R&D team before a program — benefits from seeing the terrain first. The cost of the study is a rounding error against the cost of the mistakes it prevents.
Data Sources
The market and patent figures in this medical device patent landscape case study come from:
- WIPO World Intellectual Property Indicators 2024 — 165,823 published medical-technology applications in 2024, 4.9% of global filings, +7.1%
- WIPO Patent Cooperation Treaty Yearly Review 2026 — Medical technology 6.3% of ~275,900 PCT applications in 2025, fifth-largest field
- EPO Technology Dashboard 2025 — 15,900+ EPO medtech applications in 2025 (+1.2%), 7.9% of total, 77% grant rate
- MarketsandMarkets — Surgical Robots Market — Surgical robots market forecast to ~$27.1bn by 2030 (~14.7% CAGR)
Discuss a Similar Matter
Entering a crowded device field? We will map who owns it before you commit the R&D budget.
Discuss a Similar Matter
Related PerspireIP work: Competitive IP Intelligence service · Medical device patent landscape page · how patent landscape analysis works.
Frequently Asked Questions
What is a medical device patent landscape case study?
It is a structured review of the patents in a device technology area — who files, in which classifications, and which claims are actually granted and in force — written up so a decision-maker can act on it. This representative scenario shows the method applied end to end.
How many medical-technology patents are filed each year?
WIPO recorded 165,823 published medical-technology applications in 2024 (4.9% of all filings, up 7.1%). The EPO received more than 15,900 medtech applications in 2025, 7.9% of its total and the fourth-largest field.
Which companies hold the most medical device patents?
Public landscape data puts Terumo, Philips and Medtronic among the heaviest device filers, while surgical-robotics volume is led by Johnson & Johnson, Medtronic and the fast-rising CMR Surgical. Volume leaders are not always the holders of the blocking granted claims.
Does a high filing count mean I cannot build in the space?
No. Filing counts show where attention is going; only granted, in-force claims create risk. In this scenario several hundred classification hits reduced to a few dozen genuinely enforceable families, and two subclasses were open to file into first.
How long does a landscape like this take?
This representative engagement ran from kickoff to a board-ready readout in six weeks: a classification-anchored search, assignee benchmarking, a claim read of the top families, and a white-space pass.